Adicet Bio (LTS:0HX7) Stock Based Compensation: $10.92 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HX7 Adicet Bio Inc LTS:0HX7
31 GF Score
Price $9.10
! 2 Warning Signs
View Full Analysis

What is Adicet Bio Stock Based Compensation?

Adicet Bio LTS:0HX7 -1.83% 31 Stock Based Compensation is $10.92 Mil as of Jun. 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Adicet Bio's Stock Based Compensation for the three months ended in Jun. 2026 was $1.44 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was $10.92 Mil.

Adicet Bio Stock Based Compensation Related Terms

Adicet Bio Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Stock Based Compensation Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 12.51 17.13 20.26 22.23 14.27

Adicet Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.91 2.53 5.65 1.30 1.44
LTS:0HX7
31GF Score
Adicet Bio Inc LTS:0HX7
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.92 Mil.

What does a Stock Based Compensation of $10.92 Mil mean?
Adicet Bio (LTS:0HX7) has a Stock Based Compensation of $10.92 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Adicet Bio and its competitors.
Is Adicet Bio's Stock Based Compensation too high?
Adicet Bio's current Stock Based Compensation is $10.92 Mil. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Stock Based Compensation compare to ATRA and PYPD?
Adicet Bio's Stock Based Compensation of $10.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Adicet Bio and its competitors. Adicet Bio's current Stock Based Compensation is $10.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (LTS:0HX7) has a current Stock Based Compensation of $10.92 Mil. The current Stock Based Compensation is $10.92 Mil. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current Stock Based Compensation is $10.92 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for LTS:0HX7

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.10
Price